S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
LON:AMYT

Amryt Pharma Share Forecast, Price & News

GBX 141
-4.00 (-2.76%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
136
143.90
50-Day Range
138.25
182
52-Week Range
89.90
230
Volume
75,928 shs
Average Volume
112,280 shs
Market Capitalization
£448.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive AMYT News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.


Amryt Pharma logo

About Amryt Pharma

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Headlines

Amryt Pharma (LON:AMYT) Trading Up 2.1%
November 16, 2021 |  americanbankingnews.com
Amryt Reports Strong Q3 2021 Results
November 3, 2021 |  finance.yahoo.com
Amryt Pharma PLC : Amryt Supports Global FH Awareness Day
September 30, 2021 |  markets.businessinsider.com
Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
September 13, 2021 |  finance.yahoo.com
Cheap UK shares: 1 I am considering right now
September 11, 2021 |  fool.co.uk
Amryt Pharma PLC ADR
August 13, 2021 |  barrons.com
Amryt Pharma PLC - Holding(s) in Company
August 11, 2021 |  proactiveinvestors.com
See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
£210.24 million
Cash Flow
GBX 38.90 per share
Book Value
GBX 96.60 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£448.38 million
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Amryt Pharma (LON:AMYT) Frequently Asked Questions

How has Amryt Pharma's stock price been impacted by COVID-19 (Coronavirus)?

Amryt Pharma's stock was trading at GBX 104 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMYT shares have increased by 35.6% and is now trading at GBX 141.
View which stocks have been most impacted by COVID-19
.

Who are Amryt Pharma's key executives?

Amryt Pharma's management team includes the following people:
  • Dr. Joseph A. Wiley, CEO & Director (Age 50, Pay $1.72M)
  • Mr. Rory P. Nealon, CFO, COO & Company Sec. (Age 53, Pay $931k)
  • Ms. Elizabeth Varki Jobes J.D., Sr. VP & Global Chief Compliance Officer (Age 54)
  • Mr. John McEvoy, Gen. Counsel
  • Mr. Stephen Joyce, VP of Global Marketing
  • Ms. Julie Eastwood, Head of HR
  • Ms. Derval O'Carroll, Head of Regulatory Affairs
  • Mr. Gerry Gilligan, Head of Manufacturing Supply Chain
  • Dr. Mark Sumeray, Chief Medical Officer (Age 55)
  • Mr. David Allmond, Chief Commercial Officer

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), Concepta PLC (CPT.L) (CPT), Faroe Petroleum (FPM), Vectura Group (VEC), Xcite Energy (XEL), Bowleven (BLVN), BTG (BTG) and Cavium (CAVM).

What is Amryt Pharma's stock symbol?

Amryt Pharma trades on the London Stock Exchange (LON) under the ticker symbol "AMYT."

How do I buy shares of Amryt Pharma?

Shares of AMYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Amryt Pharma's stock price today?

One share of AMYT stock can currently be purchased for approximately GBX 141.

How much money does Amryt Pharma make?

Amryt Pharma has a market capitalization of £448.38 million and generates £210.24 million in revenue each year.

How many employees does Amryt Pharma have?

Amryt Pharma employs 2,020 workers across the globe.

What is Amryt Pharma's official website?

The official website for Amryt Pharma is www.amrytpharma.com.

Where are Amryt Pharma's headquarters?

How can I contact Amryt Pharma?

Amryt Pharma's mailing address is Ivybridge House, 1 Adam Street, LONDON, WC2N 6LE, United Kingdom. The company can be reached via phone at +44-20-34155730.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.